Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06257693 · ClinicalTrials.gov registry record · Phase 1
Enzalutamide Implants (Enolen) in Patients With Prostate Cancer
A Phase 1 study of Prostate Adenocarcinoma, sponsored by Alessa Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 56
- Enrollment target
- 7
- Study locations
NCT06257693 is a Phase 1 study of Prostate Adenocarcinoma that is actively recruiting participants, run by Alessa Therapeutics. The registered enrollment target is 56 participants, below the 218-participant average among 99 other Prostate Adenocarcinoma trials with a reported enrollment target (74% lower). The trial reports 7 study locations across 7 states.
The verdict
NCT06257693, a Phase 1 study of Prostate Adenocarcinoma, is actively recruiting participants, sponsored by Alessa Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 56 participants
- Enrollment target
- 7
- Study locations
Study Summary
The study is to assess whether the Enolen is safe and delivers anti-androgen medication locally in patients that are planning for radical prostatectomy.
Conditions Studied
Interventions
- DRUG enzalutamide
Study Locations (7)
Illinois
- Northwestern University - Chicago
Louisiana
- Mary Bird Cancer Center - Metairie
Maryland
- National Institutes of Health Clinical Center - Bethesda
Oregon
- VA Portland Health Care System - Portland
South Carolina
- Atlantic Urology Specialists - Myrtle Beach
Virginia
- Virginia Commonwealth University - Richmond
Wisconsin
- Aurora Urology - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2024-06-21 |
| Est. Completion | 2028-08-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06257693
The ClinicalTrials.gov registry entry for NCT06257693 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 218-participant average among 99 other Prostate Adenocarcinoma trials with a reported enrollment target (74% lower). The listed sponsor is Alessa Therapeutics, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Prostate Adenocarcinoma appearing as the primary indexed condition, and to 1 intervention - of which enzalutamide is the first listed.
NCT06257693 reports 7 study locations spanning 7 distinct geographic areas - top geographies include Illinois, Louisiana, Maryland.
Frequently Asked Questions
What is clinical trial NCT06257693 about?
NCT06257693 is a clinical study titled "Enzalutamide Implants (Enolen) in Patients With Prostate Cancer". The study is to assess whether the Enolen is safe and delivers anti-androgen medication locally in patients that are planning for radical prostatectomy.
What is the current status of trial NCT06257693?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 56 participants. The study started on 2024-06-21. Estimated completion is 2028-08-30.
What conditions does trial NCT06257693 study?
This clinical trial studies the following conditions: Prostate Adenocarcinoma.
What interventions are being tested in trial NCT06257693?
The interventions under investigation include: enzalutamide (DRUG).
Who is sponsoring clinical trial NCT06257693?
This trial is sponsored by Alessa Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06257693 being conducted?
This trial has 7 study locations across Illinois, Louisiana, Maryland, Oregon, South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
RECRUITING · Phase 1
-
PSMA PET Response Guided SabR in High Risk Pca
RECRUITING · Phase 1
-
Hypofractionated Accelerated Pelvic Nodal Radiotherapy (GCC 2048)
RECRUITING · Phase 1
-
A Phase I Trial of 61Cu-NODAGA-PSMA for Patients with Prostate Cancer
RECRUITING · Phase 1
-
Bicalutamide Implants (Biolen) With Radiation Therapy in Patients With Localized Prostate Cancer
ACTIVE NOT RECRUITING · Phase 1
-
Radioligand Therapy After PSMA PET Guided External Beam Radiotherapy for Treating Post-Prostatectomy Patients With Biochemically Recurrent Prostate Cancer
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.